Form 4: Bicycle Therapeutics CFO Sells Shares for Tax & 10b5-1 Plan

Bicycle Therapeutics CFO Alethia Young sold 482 ordinary shares on October 2, 2025, for tax obligations and under a pre-arranged 10b5-1 trading plan.

Summary

• Alethia Young, Chief Financial Officer of Bicycle Therapeutics PLC, reported the sale of 482 ordinary shares.
• The transactions occurred on October 2, 2025.
• A total of 217 shares were sold at a weighted average price of $8.4 per share to cover statutory tax withholding obligations related to the vesting and settlement of restricted stock units.
• An additional 265 shares were sold at a price of $8.605 per share, executed under a Rule 10b5-1 trading plan adopted on April 3, 2025.
• Following these transactions, Alethia Young beneficially owns 44,704 ordinary shares directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the reported transactions are routine insider sales for tax obligations and under a pre-arranged trading plan, not indicative of a change in company fundamentals or management's outlook.

Positives

• The sale of 217 shares was non-discretionary, mandated by the award agreement to satisfy minimum statutory tax withholding obligations, indicating routine financial management.
• The sale of 265 shares was conducted under a pre-arranged Rule 10b5-1 trading plan, adopted well in advance on April 3, 2025, which promotes transparency and reduces concerns about opportunistic insider trading.

Negatives

• The transactions resulted in a reduction of Alethia Young's direct beneficial ownership of ordinary shares by 482 units.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing details routine insider transactions and does not provide information relevant to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but the routine nature of the sales (tax cover, 10b5-1 plan) suggests no significant negative implications for shareholder confidence.

Key Dates

Recommendation

The filing details routine insider stock sales for tax purposes and under a pre-arranged 10b5-1 plan. These transactions are not typically indicative of a change in the company's fundamental prospects or management's confidence, and therefore, do not provide sufficient new information to alter an existing investment thesis. A 'hold' recommendation is appropriate as this filing alone does not warrant a change in investment strategy.

Keywords

Bicycle Therapeutics, BCYC, Form 4, Insider Trading, Stock Sale, CFO, Alethia Young, 10b5-1 Plan, Restricted Stock Units, Tax Withholding